Overview

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Imatinib Mesylate